tetano
Editor, Senior Moderator
Int Immunopharmacol
. 2024 Jan 17:128:111534.
doi: 10.1016/j.intimp.2024.111534. Online ahead of print. The effects of Annual SZ drug on dynamic changes in lymphocytes and cytokines of COVID-19 patients: A randomized clinical trial
Ehsan Soltaninejad[SUP] 1 [/SUP], Zuhair Mohammad Hassan[SUP] 1 [/SUP], Mir Saeed Yekaninejad[SUP] 2 [/SUP], Mehdi Hassaniazad[SUP] 3 [/SUP], Elham Barahimi[SUP] 3 [/SUP], Afshin Samiei[SUP] 4 [/SUP], Masoumeh Ebtekar[SUP] 5 [/SUP]
Affiliations
Background: The search for a potent anti-coronavirus therapy has remained an overwhelming task since the outbreak of COVID-19. Annual SZ is a novel formulation of artemisinin and its derivatives. We aim to investigate the effect of Annual SZ on clinical outcomes, cellular immune responses, and cytokine changes in COVID-19 patients.
Methods: This study included 80 COVID-19 hospitalized patients, which were randomly allocated into two groups (intervention and control). Both groups received standard supportive treatment. In addition, the intervention group (n = 40) received Annual SZ syrup, and the control group (n = 40) received a placebo. Dynamic changes in lymphocytes, cytokines, and clinical status were evaluated since hospital admission to 7 and 14 days after treatment.
Results: The dynamic count of total T lymphocytes and T lymphocyte subsets (CD4+ and CD8+) in the Annual SZ group was significantly higher than the placebo group (p < 0.05). In addition, Programmed Death 1 (PD-1) was significantly increased in the CD4+ and CD8+ T cells in the placebo group compared with the Annual SZ group (p < 0.05). Also, the CD4+/CD8+ ratio was not significantly different between the groups (p > 0.9). Moreover, IL-6 levels were significantly reduced (p < 0.05), while IL-4 and IFN-γ levels were not statistically different between the two groups (p > 0.05).
Conclusion: This research indicated that the Annual SZ syrup significantly improved clinical status and lymphocyte frequency with less exhaustion of T lymphocytes and a reduction of inflammatory responses, which seems to be beneficial in the treatment process of COVID-19 patients.
Keywords: Annual SZ; Artemisinin; COVID-19 treatment; Cytokines; Lymphocytes; T cell exhaustion.
. 2024 Jan 17:128:111534.
doi: 10.1016/j.intimp.2024.111534. Online ahead of print. The effects of Annual SZ drug on dynamic changes in lymphocytes and cytokines of COVID-19 patients: A randomized clinical trial
Ehsan Soltaninejad[SUP] 1 [/SUP], Zuhair Mohammad Hassan[SUP] 1 [/SUP], Mir Saeed Yekaninejad[SUP] 2 [/SUP], Mehdi Hassaniazad[SUP] 3 [/SUP], Elham Barahimi[SUP] 3 [/SUP], Afshin Samiei[SUP] 4 [/SUP], Masoumeh Ebtekar[SUP] 5 [/SUP]
Affiliations
- PMID: 38237225
- DOI: 10.1016/j.intimp.2024.111534
Background: The search for a potent anti-coronavirus therapy has remained an overwhelming task since the outbreak of COVID-19. Annual SZ is a novel formulation of artemisinin and its derivatives. We aim to investigate the effect of Annual SZ on clinical outcomes, cellular immune responses, and cytokine changes in COVID-19 patients.
Methods: This study included 80 COVID-19 hospitalized patients, which were randomly allocated into two groups (intervention and control). Both groups received standard supportive treatment. In addition, the intervention group (n = 40) received Annual SZ syrup, and the control group (n = 40) received a placebo. Dynamic changes in lymphocytes, cytokines, and clinical status were evaluated since hospital admission to 7 and 14 days after treatment.
Results: The dynamic count of total T lymphocytes and T lymphocyte subsets (CD4+ and CD8+) in the Annual SZ group was significantly higher than the placebo group (p < 0.05). In addition, Programmed Death 1 (PD-1) was significantly increased in the CD4+ and CD8+ T cells in the placebo group compared with the Annual SZ group (p < 0.05). Also, the CD4+/CD8+ ratio was not significantly different between the groups (p > 0.9). Moreover, IL-6 levels were significantly reduced (p < 0.05), while IL-4 and IFN-γ levels were not statistically different between the two groups (p > 0.05).
Conclusion: This research indicated that the Annual SZ syrup significantly improved clinical status and lymphocyte frequency with less exhaustion of T lymphocytes and a reduction of inflammatory responses, which seems to be beneficial in the treatment process of COVID-19 patients.
Keywords: Annual SZ; Artemisinin; COVID-19 treatment; Cytokines; Lymphocytes; T cell exhaustion.